Effect of a Nursing Program for Patients With Cystic Fibrosis on Disease Management

Auswirkung Eines CF Nursing-Programms Auf Das Krankheitsmanagement Und Die Erfahrungen Der Behandlung Von Patientinnen Und Patienten

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02286050

Enrollment

Registered

2014-11-07

Start date

2014-11-30

Completion date

2017-04-30

Last updated

2017-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Brief summary

The purpose of this study is to evaluate the effect of a nursing program in patients with cystic fibrosis.

Detailed description

All patients living with cystic fibrosis will be asked by questionnaire before (November 2014) and after (September 2016) the implementation of the program about their satisfaction with treatment, trust in the CF-Team, adherence, self-efficacy, treatment burden and quality of life.

Interventions

OTHERCF Nursing Program

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Cystic Fibrosis

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Difference between baseline patient satisfaction and month 22	month 22	Self-reported patient satisfaction will be measured with a newly developped questionnaire.

Secondary

Measure	Time frame	Description
Difference between baseline adherence and month 22	month 22	Self-reported adherence to therapy will be measured with the Medication Adherence Report Scale (MARS) and a newly developped questionnaire.
Difference between baseline self-efficacy and month 22	month 22	Self-reported self-efficacy to master the the therapeutic regimen will be measured with a newly developped questionnaire.
Difference between baseline trust and month 22	month 22	Self-reported trust will be measured with the short version of the Wake Forest Trust Scale.
Difference between baseline information need and month 22	month 22	Information needs will be assessed with a subscale of the PICKER-questionnaire for patients with CF.
Difference between baseline treatment burden and month 22	month 22	Self-reported treatment burden will be measured wiht a subscale of the CFQ-R.

Other

Measure	Time frame	Description
Difference between baseline QoL and month 22	month 22	Self-reported QoL will be measured with the Cystic Fibrosis Questionnaire - revised (CFQ-R) and the VAS of the European Quality of Life Instrument - 5 dimensions (EQ-5D VAS).

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026